Potential low-cost options for monitoring HIV-1-infected children in less-developed countries

November 13, 2003

Authors of a research letter in this week's issue of THE LANCET highlight how assessment of total blood lymphocyte count and albumen concentrations could have potential as low-cost alternatives in assessing the disease status of HIV-1-infected children in less-developed countries.

The cost of laboratory analysis of CD4 lymphocyte count and viral-load assessment (conventional procedures in industrialised countries) is more expensive than the cost of antiretroviral drugs in some resource-poor settings. Lynne Mofenson from the US National Institutes of Health, and colleagues assessed the prognostic value of five measures (total lymphocyte count, immune complex-dissociated p24 antigen, white blood cell count, packed-cell volume, and blood albumin) for death in 376 HIV-1-infected children. The investigators found that total lymphocyte count and albumin independently predicted the risk of death in HIV-1-infected children of all ages.

Lynne Mofenson comments: "Use of one or more of these assays could serve as relatively inexpensive means to establish when to initiate antiretroviral therapy in children in settings where CD4 and RNA assays are not available. Total lymphocyte count remained predictive even when CD4 and RNA values were known."

In an accompanying Commentary (p1597), François Dabis from INSERM, France,concludes: "The urgency now is to start HAART in as many African HIV-infected children as possible because the disease burden is unacceptable. Children born to HIV-infected mothers who fail one of the interventions for peripartum mother-to-child transmission of HIV are an obvious target, assuming early diagnosis of paediatric HIV is widely implemented with the same low-cost technologies. Older children in the same families should also be offered diagnosis and treatment. Children's clinics could be another portal of entry for proposing HIV screening and starting treatment to more children. Finally, we should not forget that many HIV-infected children are particularly vulnerable and in need of treatment are orphaned. Reducing the proportion of infants infected by HIV by 20% by 2005 is not an easy target set by WHO, and requires that all solutions are implemented at the same time. Antiretroviral therapy of children is now clearly one of them for Africa."
-end-
Contact: Robert Bock, Public Information and Communications Branch, National Institute of Child Health and Human Development, National Institutes of Health;
Building 31 Room 2A32, MSC2425, Bethesda, MD 20892 USA;
T) 301-496-5133;
F) 301-496-4757;
E) bockR@mail.nih.gov

Dr François Dabis, INSERM U593, Institut de Santé Publique, Epidémiologie et Développement, Université Victor Segalen;
33076 Bordeaux Cedex, France;
E) francois.dabis@isped.u-bordeaux2.fr

Lancet 2003; 362: 1597, 1625-27

Lancet

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.